Logo
x

Search

Subscribe Now

renal cell carcinoma

Merck’s Keytruda + Lenvima Receives MHLW’s Approval in Japan to Treat Renal Cell Carcinoma

Merck’s Keytruda + Lenvima Receives MHLW’s Approval in Japan to Treat Renal Cell Carcinoma

  • February 28, 2022
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma

  • November 19, 2021
BMS Reports Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -214 for the Treatment of Advanced or Metastatic Renal Cell Carcinoma

BMS Reports Five-Year Data of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate -214 for the Treatment of Advanced or Me...

  • September 16, 2021
Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metast...

  • August 25, 2021
Merck Presents Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 as Adjuvant Therapy for Renal Cell Carcinoma at ASC0 2021

Merck Presents Results of Keytruda (pembrolizumab) in P-III KEYNOTE-564 as Adjuvant Therapy for Renal Cell Carcinoma at ASC0 2021

  • June 4, 2021
BMS' Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive EC's Approval for 1L Treatment of Advanced Renal Cell Carcinoma

BMS' Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive EC's Approval for 1L Treatment of Advanced Renal Cell Carcinoma

  • April 15, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.